

Please type a plus sign (+) inside this box →



11-08-00

PTO/SB/05 (08/00)

Approved for use through 09/30/00. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

Attorney Docket No.

16778-704

(Only for new nonprovisional applications under 37 CFR 1.53(b))

First Inventor or Application Identifier

Craig Hill et al.

Title

Compounds for Intracellular Delivery of Therapeutic Molecules to Nerve Cells

Express Mail Label No.

EL473791337US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

- 1.
- ☐
- Fee Transmittal Form (e.g., PTO/SB/17)

(Submit an original, and a duplicate for fee processing)

- 2.
- ☐
- Applicant claims small entity status. See 37 CFR 1.27.

- 3.
- ☒
- Specification

[Total Pages 40]

(preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed-Sponsored R&D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Detailed Description of the Drawings
- Detailed Description
- Claim(s)

- 4.
- ☐
- Drawing(s) (37CFR 1.152)

[Total Sheets 0]

- 5.
- ☐
- Oath or Declaration

[Total Pages 1]

- a.
- ☐
- Newly executed (original or copy)

- b.
- ☐
- Copy from a prior application (37 CFR 1.63(d))

(for continuation/divisional with Box 17 completed)

- i.
- ☐
- DELETION OF INVENTOR(S)**

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

- 6.
- ☐
- Application Data Sheet. See 37 CFR 1.76

- 7.
- ☐
- Microfiche Computer Program (Appendix)

- 8.
- ☐
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

- a.
- ☒
- Computer Readable Copy

- b.
- ☒
- Paper Copy (identical to computer copy)

- c.
- ☒
- Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

- 9.
- ☐
- Assignment Papers (cover sheet & document(s))

- 10.
- ☐
- 37 CFR 3.73(b) Statement
- ☐
- Power of Attorney (when there is an assignee)

- 11.
- ☐
- English Translation Document (if applicable)

- 12.
- ☐
- Information Disclosure Statement (IDS)
- ☐
- Copies of IDS Citations

- 13.
- ☐
- Preliminary Amendment

- 14.
- ☒
- Return Receipt Postcard (MPEP 503) (Should be specifically itemized)

- 15.
- ☐
- Certified Copy of Priority Document(s) (if foreign priority is claimed)

- 16.
- ☒
- Other: Express Mail Statement (37 CFR 1.10)

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional☒ Continuation-in-part (CIP) of prior application No. 09/217,037Prior application information: Examiner S. TurnerGroup/Art Unit: 1647

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**18. CORRESPONDENCE ADDRESS**☒ Customer Number or Bar Code Label

021971

or ☐ Correspondence address below

(Insert Customer No. or Attach bar code label here)

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

Name (Print/Type)

David J. Weitz

Registration No. (Attorney/Agent)

38,362

Signature

Date

Nov. 6, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Document

**Compounds For Intracellular Delivery  
Of Therapeutic Moieties To Nerve Cells**

Inventors: Craig Hill, Steve Kahl,  
Robert R. Webb, and Constance A. McKee

**BACKGROUND OF THE INVENTION**

**Relationship to Copending Applications**

- 5           This application is a continuation-in-part of copending U.S. Application Serial No. 09/217,037 entitled *COMPOUNDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOITIES TO NERVE CELLS*, filed December 21, 1998, which is incorporated herein by reference.

**Field of the Invention**

- 10           The present invention relates to compounds which can be used to selectively deliver moieties to nerve cells. More specifically, the invention relates to compounds which include a therapeutic moiety and facilitate absorption of the therapeutic moiety by nerve cells.

15           **Description of Related Art**

- Our understanding of the structure and function of the nervous system has been greatly advanced owing to enormous progresses made in field of neuroscience. Cellular and molecular mechanisms of neuron growth and development and diseases associated with the central and peripheral nervous systems are studied extensively by using rapidly growing techniques in molecular and cell biology. However, a need still exists for efficacious treatments of many neurological disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, severe pain, multiple sclerosis, bipolar disease, and diseases of the nervous system due to infection by viruses and other microorganisms (herpes simplex, HIV, cytomegalovirus, parasites, fungi, prion, etc.).
- 20
- 25

Many neuropharmaceutical agents have been developed to treat diseases of the nervous system, but their usefulness has been hampered by severe side effects partially due to nonspecific interactions between these agents and cells or tissues other than the targeted cells. For example, steroid hormone cortisone and its derivatives are widely used to treat inflammation in the body including the nerve system to reduce symptoms such as swelling, tenderness and pain. However, the steroid dosage has to be kept at the lowest effective level because of its severe side effects. Steroid hormone binds to its cognate nuclear hormone receptor and induces a cascade of cellular effects, including programmed cell death of the neurons in the brain (Kawata M., et al., J. Steroid Biochem. Mol. Biol. 65: 273-280 (1998)). Since steroid hormone receptors, such as glucocorticoid receptor for cortisone, distribute in a wide variety of tissues and cells, nonspecific interactions of the hormone with its cognate receptor in different sites is unavoidable if the drug is circulated systemically.

A need continues to exist for an effective system for delivering therapeutic agents selectively to nerve cells and nerve tissues. Various techniques have been developed to deliver drugs, but with only limited success. For example, liposomes have been used as carrier molecules to deliver a broad spectrum of agents including small molecules, DNAs, RNAs, and proteins. Liposome mediated delivery of pharmaceutical agents has major drawbacks because of its lack of target specificity. Attempts have been made to overcome this problem by covalently attaching whole site-specific antibody or Fab fragments to liposomes containing a pharmaceutical agent (Martin et al., Biochem. 20, 4229-4238, (1981)). However, an intrinsic problem of particular importance in any liposome carrier system is that in most cases the targeted liposome does not selectively reach its target site *in vivo*. Whether or not liposomes are coated with antibody molecules, liposomes are readily phagocytosed by macrophages and removed from circulation before reaching their target sites.

## SUMMARY OF THE INVENTION

Compounds of the present invention include compounds having the  
5 general formula:

### B-L-M

where:

10 **B** is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;

**M** is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell; and

15 **L** is a linker coupling **B** to **M**.

In one embodiment, the compounds have the general formula:

### B-L-TM

20

where:

**B** is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;

25 **TM** is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a nerve cell; and

**L** is a linker coupling **B** to **TM**.

In another embodiment, the compounds have the general formula:

30

### B-L-IM

where:

**B** is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;

5 **IM** is a non-cytotoxic imaging moiety which can be used to image a nerve cell or an intracellular component of the nerve cell; and

**L** is a linker coupling **B** to **IM**.

In regard to each of the above embodiments, particular classes of  
10 binding agents **B** which may be used include, but are not limited to, nucleic acid sequences, peptides, peptidomimetics, antibodies and antibody fragments. Examples of nucleic acids that can serve as the binding agent **B** include, but are not limited to, DNA and RNA ligands that function as antagonists of nerve growth factors or inhibit binding of other growth  
15 factors to nerve cell surface receptors. Examples of peptides that can serve as the binding agent **B** include, but are not limited to, members of the nerve growth factors (neurotrophin) family such as NGF, BDNF, NT-3, NT-4, NT-6; derivatives, analogs, and fragments of nerve growth factors such as recombinant molecules of NGF and BDNF; and synthetic peptides  
20 that bind to nerve cell surface receptors and have agonist or antagonist activities of nerve growth factors.

Antibodies, derivatives of antibodies and antibody fragments can also serve as the binding agent **B**. Examples of this type of binding agent **B** include, but are not limited to, anti-human trkA monoclonal antibody 5C3  
25 and anti-human p75 monoclonal antibody MC192.

The therapeutic moiety **TM** is selected to perform a non-cytotoxic therapeutic function within nerve cells. Examples of non-cytotoxic functions which the therapeutic moiety **TM** may perform include, but are not limited to, the functions performed by adrenergic agents, analgesics,  
30 anti-trauma agents, anti-viral agents, gene therapy agents, and hormones (growth factors, interferons, etc.). Examples of classes of therapeutic moieties include, but are not limited to, adrenergic agents (e.g.,

epinephrine, norepinephrine, dopamine, etenolol), analgesics (e.g., opioids, codeine, oxycodone), anti-trauma agents, anti-viral agents (e.g., acyclovir, gancyclovir, AZT, ddI, ddC, etc.), gene therapy agents (e.g., DNAs or RNAs which introduce a gene or replace a mutated gene),  
5 steroids (e.g., cortisone, progesterone, estrogen), and hormones (e.g., growth factors, interferons).

In one particular embodiment, the therapeutic moiety **TM** is a charged moiety. Cells have difficulty transporting charged molecules across cell membranes. According to this embodiment, the binding agent  
10 **B** serves to facilitate transport of a charged therapeutic moiety **TM** into a cell. Within the cell, the compound (i.e. the conjugate formed between **B** and **TM**) is metabolized to form a metabolite product that comprises the charged therapeutic moiety **TM**. The metabolite product is less prone to being transported across the cell membrane out of the cell relative to the  
15 conjugate because of the metabolism of the conjugate resulting in the separation of the therapeutic moiety **TM** from the binding agent **B**. The metabolite product is also less prone to being transported across the cell membrane out of the cell relative to a non-charged version of the therapeutic moiety due to the charge which the therapeutic moiety carries.

According to this embodiment, compounds are provided which  
20 comprise a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell, the cell metabolizing at least a portion of the protein to form a charged  
25 metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the conjugate and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.

30 In one particular embodiment, the charged therapeutic moiety **TM** is a quaternary alkyl amine derivative of a therapeutic moiety. A particular

example of a quaternary alkyl amine derivative of a therapeutic moiety **TM** is a quaternary alkyl amine of propoxycaine, shown in Table 3.

The imaging moiety **IM** is a non-cytotoxic agent which can be used to locate and optionally visualize a nerve cell or an internal component of the nerve cell which has absorbed the imaging moiety. Fluorescent dyes may be used as an imaging moiety **IM**. Radioactive agents which are non-cytotoxic may also be an imaging moiety **IM**.

In general, the linker may be any moiety which can be used to link the binding agent **B** to the moiety **M**. In one particular embodiment, the linker is a cleavable linker. The use of a cleavable linker enables the moiety **M** linked to the binding agent **B** to be released from the compound once absorbed by the nerve cell. The cleavable linker may be cleaved by a chemical agent, enzymatically, due to a pH change, or by being exposed to energy. Examples of forms of energy which may be used include light, microwave, ultrasound, and radiofrequency.

The present invention also relates to a method for selectively delivering a moiety into nerve cells comprising the steps of:

delivering to a patient a compound having the general formula:

### **B-L-M**

where:

**B** is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;

**M** is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell; and

**L** is a linker coupling **B** to **M**.

having the compound selectively bind to a nerve cell surface receptor via the binding agent **B**; and

having the compound be absorbed by the nerve cell mediated by the binding of the binding agent **B** to the nerve cell surface receptor.

In one embodiment, moiety **M** is a therapeutic moiety **TM** as described herein and in another embodiment is an imaging moiety **IM**.

The above method can be used to deliver therapeutic moieties for treating a variety of neurological disorders when the therapeutic moiety **TM** is a moiety useful for treating such neurological disorders.

The above method can be used to deliver therapeutic moieties for treating pain when a therapeutic moiety **TM** for treating pain, such as an analgesic, is included as the therapeutic moiety **TM** in the compound.

The above method can also be used to deliver steroid hormones for treating nerve damage when a therapeutic moiety **TM** for treating nerve damage, such as a steroid hormone, is included as the therapeutic moiety **TM** in the compound.

The above method can also be used to stimulate nerve growth when a therapeutic moiety **TM** for inducing the production of a nerve growth factor is included as the therapeutic moiety **TM** in the compound.

The above method can also be used to treat infected nerve cells infected with viruses or immunize nerve cells from viruses when the therapeutic moiety **TM** in the compound is an antiviral agent.

The above method can also be used to perform gene therapy when the therapeutic moiety **TM** is a gene therapy agent.

The present invention also relates to a method for improving intracellular administration of a therapeutic agent. The method comprises contacting cells with a compound comprising a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell; and having the cell transport the compound into the cell where the cell metabolizes at least a portion of the protein to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the conjugate and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.



In one embodiment, this method is used in conjunction with the conjugates of the present invention and hence is used in conjunction with the methods of the present invention for selectively delivering a moiety into nerve cells.

- 5 In one particular embodiment, the charged therapeutic moiety **TM** is a quaternary alkyl amine derivative of a therapeutic moiety. A particular example of a quaternary alkyl amine derivative of a therapeutic moiety **TM** is a quaternary alkyl amine of propoxycaine, shown in Table 3.

10

## DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds which include a binding agent which binds to a nerve cell surface receptor and facilitates absorption of the compound by the nerve cell; and a moiety. Different Moieties may be included in the compounds of the present invention including therapeutic moieties that are non-cytotoxic to the nerve cells and imaging moieties which can be used to image nerve cells which absorb these compounds.

In one embodiment, compounds of the present invention have the general formula:

### **B-L-TM**

where:

**B** is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;

**TM** is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a nerve cell; and

**L** is a linker coupling **B** to **TM**.

According to this embodiment, the binding agent **B** serves as a homing agent for nerve cells by selectively binding to nerve cell surface receptors. The binding agent **B** also serves to facilitate absorption of the compound by the nerve cell. The binding agent **B** can be any molecule which can perform these two functions. Particular classes of binding agents which may be used include, but are not limited to, nucleic acid sequences, peptides, peptidomimetics, antibodies and antibody fragments.

Examples of nucleic acids that can serve as the binding agent **B** include, but are not limited to, DNA and RNA ligands that function as antagonists of nerve growth factors or inhibit binding of other growth

factors to nerve cell surface receptors (Binkley, J., et al., Nucleic Acid Res. 23: 3198-3205 (1995); Jellinek, D., et al., Biochem. 33:10450-10456 (1994)).

Examples of peptides that can serve as the binding agent **B** include, but are not limited to, members of the nerve growth factors (neurotrophin) family such as NGF, BDNF, NT-3, NT-4, NT-6, etc. (see reviews: Frade, J. M., et al., Bioessays 20: 137-145 (1998); Shieh, P. B., Curr. Biol. 7: R627-R630 (1997); Dechant, G., et al., Curr. Opin. Neurobiol. 7: 413-418 (1997); Chao, M. V. and Hempstead, B. L., Trends Neurobiol. 18: 321-326 (1995)); and derivatives, analogs, and fragments of nerve growth factors such as recombinant molecules of NGF and BDNF (Ibanez et al., EMBO J. 10: 2105-2110; Ibanez et al., EMBO J. 12: 2281-2293), synthetic peptides that bind to nerve cell surface receptors and have agonist or antagonist activities of nerve growth factors (Longo, F. M., et al., Cell Regulation 1: 189-195 (1990); LeSauter, L. et al., J. Biol. Chem. 270: 6564-6569 (1995); Longo F. M., et al., J. Neurosci. Res. 48: 1-17; Longo, et al., Nature Biotech. 14: 1120-1122 (1997)).

Examples of antibodies, derivatives of antibodies and antibody fragments that can serve as the binding agent **B** include, but are not limited to, anti-human trkA monoclonal antibody 5C3 (Kramer, K., et al., Eur. J. Cancer 33: 2020-2091 (1997)), anti-human p75 monoclonal antibody MC192 (Maliatchouk, S. and Saragovi, H. U., J. Neurosci. 17: 6031-7).

According to this embodiment, the therapeutic moiety **TM** is selected to perform a non-cytotoxic therapeutic function within nerve cells.

Examples of non-cytotoxic functions which the therapeutic moiety **TM** may perform include, but are not limited to, the functions performed by analgesics, anti-trauma agents, anti-viral agents, gene therapy agents, and hormones (growth factors, interferons, etc.). Examples of classes of therapeutic moieties include, but are not limited to, adrenergic agents (e.g., epinephrine, norepinephrine, dopamine, etenolol), analgesics (e.g., opioids, codeine, oxycodone), anti-trauma agents, anti-viral agents (e.g., acyclovir, gancyclovir, AZT, ddI, ddC, etc.), gene therapy agents (e.g.,

DNAs or RNAs which introduce a gene or replace a mutated gene), steroids (e.g., cortisone, progesterone, estrogen), and hormones (e.g., growth factors, interferons).

5 The linker **L** serves to link the binding agent **B** to the therapeutic moiety **TM**. A wide variety of linkers are known in the art for linking two molecules together, particularly, for linking a moiety to a peptide or nucleic acid, all of which are included within the scope of the present invention.

Examples of classes of linkers that may be used to link the binding agent **B** to the therapeutic moiety **TM** include amide, alkylamine, 10 thioether, alkyl, cycloalkyl, aryl linkages such as those described in Hermanson, G.T., Bioconjugate Techniques (1996), Academic Press, San Diego, CA.

In certain applications, it is desirable to release the therapeutic moiety **TM** once the compound has entered the nerve cell, resulting in a 15 release of the therapeutic moiety **TM**. Accordingly, in one variation, the linker **L** is a cleavable linker. This enables the therapeutic moiety **TM** to be released from the compound once absorbed by the nerve cell. This may be desirable when the therapeutic moiety **TM** has a greater therapeutic effect when separated from the binding agent. The therapeutic moiety **TM** 20 may have a better ability to be absorbed by an intracellular component of the nerve cell when separated from the binding agent. Accordingly, it may be necessary or desirable to separate the therapeutic moiety **TM** from the compound so that the therapeutic moiety **TM** can enter the intracellular compartment.

25 Cleavage of the linker releasing the therapeutic moiety may be as a result of a change in conditions within the nerve cells as compared to outside the nerve cells, for example, due to a change in pH within the nerve cell. Cleavage of the linker may occur due to the presence of an enzyme within the nerve cell which cleaves the linker once the compound 30 enters the nerve cell. Alternatively, cleavage of the linker may occur in response to energy or a chemical being applied to the nerve cell. Examples of types of energies that may be used to effect cleavage of the

linker include, but are not limited to light, ultrasound, microwave and radiofrequency energy.

The linker **L** used to link the binding agent **B** to the therapeutic moiety **TM** may be a photolabile linker. Examples of photolabile linkers include those linkers described in US Patent No. 5,767,288 and No. 4,469,774. The linker **L** used to link the binding agent **B** to the therapeutic moiety **TM** may also be an acid labile linker. Examples of acid labile linkers include linkers formed by using cis-aconitic acid, cis-carboxylic alkatriene, polymaleic anhydride, and other acidlabile linkers, such as those linkers described in US Patent Nos. 5,563,250 and 5,505, 931.

Further examples of cleavable linkers include, but are not limited to the linkers described in Lin, et al., J. Org. Chem. 56:6850-6856 (1991); Ph.D. Thesis of W.-C. Lin, U.C. Riverside, (1990); Hobart, et al., J. Immunological Methods 153: 93-98 (1992) ; Jayabaskaran, et al., Preparative Biochemistry 17(2): 121-141 (1987); Mouton, et al., Archives of Biochemistry and Biophysics 218: 101-108 (1982) ; Funkakoshi, et al., J. of Chromatography 638:21-27 (1993); Gildea, et al., Tetrahedron Letters 31: 7095-7098 (1990); WO 85/04674; and Dynabeads™ (Dynal, Inc., 5 Delaware Drive, Lake Success, NY 11042).

In another embodiment, compounds of the present invention have the general formula:

### **B-L-IM**

where:

**B** is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;

**IM** is a non-cytotoxic imaging moiety which can be used to image the nerve cell or an intracellular component of the nerve cell; and

**L** is a linker coupling **B** to **IM**.

According to this embodiment, the binding agent **B** and linker **L** may be varied as described above with regard to compounds having the general formula **B-L-TM**. Further according to this embodiment, the imaging moiety **IM** may be a non-cytotoxic moiety which can be used to image nerve cells. Examples of imaging moieties that may be used include fluorescent dyes and radioisotopes which are non-cytotoxic.

The present invention also relates to a method for selectively delivering a non-cytotoxic therapeutic moiety into nerve cells comprising the steps of:

delivering to a patient a therapeutic amount of a compound having the general formula:

### **B-L-TM**

where:

**B** is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell,

**TM** is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a nerve cell, and

**L** is a linker coupling **B** to **TM**;

having the compound selectively bind to a nerve cell surface receptor via the binding agent **B**; and

having the compound be absorbed by the nerve cell mediated by the binding of the binding agent **B** to the nerve cell surface receptor.

The method of the present invention offers the advantage of specifically targeting a non-cytotoxic therapeutic moiety to nerve cells where the therapeutic moiety is absorbed by the nerve cells. The method utilizes the fact that internalization of the conjugated agent is mediated by the binding of the binding agent **B** to nerve cell surface receptors. Once internalized, the therapeutic moiety can accumulate within the nerve cells where it has a therapeutic effect. The ability to selectively deliver the

compound to nerve cells reduces the overall amount of therapeutic moiety which needs to be administered. Selective delivery of the therapeutic moiety to the nerve cell reduces the amount of side effects observed due to non-specific administration of the therapeutic moiety. In addition, the therapeutic moiety is less likely to be separated from the binding agent and non-specifically administered as compared to delivery methods involving the use of a binding agent and a therapeutic moiety in combination.

The method of the present invention can be used to deliver therapeutic moieties for treating a variety of neurological disorders including, but not limited to, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neurodegenerative disease, epilepsy, seizure, migraine, trauma and pain. Examples of neuropharmaceuticals that may be used include proteins, antibiotics, adrenergic agents, anticonvulsants, nucleotide analogs, anti-trauma agents, peptides and other classes of agents used to treat or prevent a neurological disorders. For example, analgesics such as opioids, codeine and oxycodone can be conjugated to the binding agent **B** and specifically delivered to the nerve cells. Since the same level of pain relief can be achieved using a smaller dosage of analgesics, side effects such as respiratory depression or potential drug addiction can be avoided or at least ameliorated. Steroid hormones such as corticosteroids can also be conjugated with nerve cell-specific binding agents and used to treat inflammation of the nerves, which may reduce the side effects associated with high doses of steroids, such as weight gain, redistribution of fat, increase in susceptibility to infection, and avascular necrosis of bone.

The method according to the present invention can also be used to deliver agents that induce the production of nerve growth factor in the target nerve cells, especially under conditions of pathogenic under-expression of NGFs (See Riaz, S. S. and Tomlinson, D. R. Prog. Neurobiol. 49: 125-143 (1996)). NGF induction has been demonstrated in a wide variety of cell types, such as fibroblasts (Furukawa, Y. et al., FEBS Lett. 247: 463-467(1989)), astrocytes (Furukawa, Y. et al., FEBS Lett. 208: 258-262 (1986)), Schwann cells (Ohi, T. et al., Biochem. Int. 20:739-

746 (1990)) with a variety of agents including cytokines, steroids, vitamins, hormones, and unidentified components of serum. Specific examples of agents known to induce NGF include 4-methylcatechol, clenbuterol, isoprenaline, L-tryptophan, 1,25-dihydroxyvitamin D3, forskolin, fellutamide  
5 A, gangliosides and quinone derivatives (Riaz, S. S. and Tomlinson, D. R. Prog. Neurobiol. 49: 125-143 (1996)).

The method according to the present invention can also be used to deliver antiviral drugs into nerve cells in order to treat diseases caused by viral infection, to eliminate viruses spread to the nerves, and to inhibit  
10 infection by such viruses. Examples of viruses that infect the nervous system include but are not limited to rabies viruses, herpes viruses, polioviruses, arboviruses, reoviruses, pseudorabies, corona viruses, and Borna disease viruses. For example, antiviral drugs such as acyclovir, gancyclovir, and Cifodovir can be conjugated to the binding agent and  
15 used to inhibit active or latent herpes simplex viruses in the peripheral and central nervous system. Specific delivery of the conjugate containing these antiviral drugs to the nervous system can reduce the side effects associated with high doses or long-term administration of these drugs, such as headaches, rash and paresthesia.

20 The method according to the present invention can also be used to deliver marker compounds to image intracellular components of the nerve cells. Such marker compounds include but are not limited to fluorescent dyes, radioactive complexes, and other luminophores.

The method according to the present invention can also be used to  
25 perform gene therapy wherein nucleic acids (DNA or RNA) are delivered to the nerve cells. These nucleic acids may serve to replace genes which are either defective, absent or otherwise not properly expressed by the patient's nerve cell genome.

30 The above and other features and advantages of the present invention will become more apparent in the following description of the preferred embodiments in greater detail.



## 1. Binding Agent (B)

According to the present invention, a compound with a binding agent **B** is used to selectively deliver the conjugated therapeutic moieties **TM** to nerve cells. At the nerve cell, the binding agent **B** interacts with a receptor on the nerve cell and is absorbed by the nerve cell mediated by this interaction. Any molecules possessing these two physical properties are intended to fall within the scope of a binding agent **B** as it is used in the present invention. In particular, peptides or proteins with these features can serve as a binding agent **B**, examples including but not limited to nerve growth factors (neurotrophins), antibodies against nerve cell-specific surface proteins, mutants and synthetic peptides derived from these peptides or proteins.

In one embodiment, neurotrophins are preferably used as the binding agent **B**. Neurotrophins are a family of small, basic polypeptides that are required for the growth, development and survival of neurons. A particular "survival" factor is taken up by the neuron via binding to one or more of a related family of transmembrane receptors. Table I lists several members of the neurotrophin family and their cognate receptors.

As listed in Table 1, nerve growth factor (NGF) is the first identified and probably the best characterized member of the neurotrophin family. It has prominent effects on developing sensory and sympathetic neurons of the peripheral nervous system. Brain-derived neurotrophic factor (BDNF) has neurotrophic activities similar to NGF, and is expressed mainly in the CNS and has been detected in the heart, lung, skeletal muscle and sciatic nerve in the periphery (Leibrock, J. et al., Nature, 341:149-152 (1989)). Neurotrophin-3 (NT-3) is the third member of the NGF family and is expressed predominantly in a subset of pyramidal and granular neurons of the hippocampus, and has been detected in the cerebellum, cerebral cortex and peripheral tissues such as liver and skeletal muscles (Ernfors, P. et al., Neuron 1: 983-996 (1990)). Neurotrophin-4 (also called NT-4/5) is

the most variable member of the neurotrophin family. Neurotrophin-6 (NT-6) was found in teleost fish and binds to p75 receptor.

As listed in Table 1 at least two classes of transmembrane glycoproteins (trk and p75) have been identified which serve as receptors for neurotrophins. The trk receptors (tyrosine kinase-containing receptor) bind to neurotrophins with high affinity, whereas the p75 receptors possess lower affinity to neurotrophins. For example, nerve growth factor (NGF) binds to a relatively small number of trkA receptors with high affinity ( $K_D = 10^{-11}$ ) and to more abundant p75 with lower affinity ( $K_D = 10^{-9}$ ). The receptor-bound NGF is internalized with membrane-bound vesicles and retrogradely transported the neuronal cell body. Thus, native neurotrophins may serve as the binding agent **B** in the compound according the present invention to deliver the conjugated therapeutic agent **TM** to the neuronal cell body.

Table 1 The Neurotrophin Family and Its Receptors.

Factor	Receptor		Responsive neurons (examples)
	Kinase isoforms	Nonkinase forms	
NGF	trkA	p75	Cholinergic forebrain neurons Sympathetic ganglia DRG nociceptive
BDNF	trkB	p75 <sup>LNTR</sup> trkB <sub>T1</sub> trkB <sub>T2</sub>	Many CNS populations Vestibular ganglia Nodose ganglia DRG mechanoreceptors
NT-3	trkC trkB and trkA Nonpreferred	p75 <sup>LNTR</sup> trkC <sup>TK-113</sup> trkC <sup>TK-108</sup>	Many CNS populations Choclear ganglia DRG proprioceptive
NT-4	trk B	p75 trkB <sub>T1</sub> trkB <sub>T2</sub>	Many CNS populations Nodose ganglia Petrosalganglia
NT-6	trkA	p75	

In addition to the neurotrophins described above, analogs and derivatives of neurotrophins may also serve as the binding agent **B**. The structure of mouse NGF has been solved by X-ray crystallography at 2.3 Å

resolution (McDonald et al., *Nature*, 345: 411-414, (1991)). Murine NGF is a dimeric molecule, with 118 amino acids per protomer. The structure of the protomer consists of three antiparallel pairs of beta strands that form a flat surface, four loop regions containing many of the variable residues between different NGF-related molecules, which may determine the different receptor specificities, and a cluster of positively charged side chains, which may provide a complementary interaction with the acidic low-affinity NGF receptor. Murine NGF has a tertiary structure based on a cluster of three cysteine disulfides and two extended, but distorted beta-hairpins. One of these  $\beta$ -hairpin loops was formed by the NGF 29-35 region. Structure/function relationship studies of NGF and NGF-related recombinant molecules demonstrated that mutations in NGF region 25-36, along with other  $\beta$ -hairpin loop and non-loop regions, significantly influenced NGF/NGF-receptor interactions (Ibanez et al., *EMBO J.*, 10, 2105-2110, (1991)). Small peptides derived from this region have been demonstrated to mimic NGF in binding to trkA receptor and affecting biological responses (LeSauter et al. *J. Biol. Chem.* 270, 6564-6569, 1995). Dimers of cyclized peptides corresponding to  $\beta$ -loop regions of NGF were found to act as partial NGF agonists in that they had both survival-promoting and NGF-inhibiting activity while monomer and linear peptides were inactive (Longo et al., *J. Neurosci. Res.*, 48, 1-17, 1997). Cyclic peptides have also been designed and synthesized to mimic the  $\beta$ -loop regions of NGF, BDNF, NT3 and NT-4/5. Certain monomers, dimers or polymers of these cyclic peptides may have a three-dimensional structure which binds to neurotrophin receptors under physiological conditions. All of these structural analogs of neurotrophins that bind to nerve cell surface receptors and are internalized can serve as the binding agent **B** of the compound according to the present invention to deliver the conjugated therapeutic moiety **TM** to the nervous system.

Alternatively, antibodies against nerve cell surface receptors that are capable of binding to the receptors and being internalized can also serve as the binding agent **B**. For example, monoclonal antibody (MAb) 5C3 is

specific for the NGF docking site of the human p140 trkA receptor, with no cross-reactivity with human trkB receptor. Mab 5C3 and its Fab mimic the effects of NGF *in vitro*, and image human trk-A positive tumors *in vivo* (Kramer et al., Eur. J. Cancer, 33, 2090-2091, (1997)). Molecular cloning ,  
5 recombination, mutagenesis and modeling studies of Mab 5C3 variable region indicated that three or less of its complementarity determining regions (CDRs) are relevant for binding to trkA. Assays with recombinant CDRs and CDR-like synthetic polypeptides demonstrated that they had agonistic bioactivities similar to intact Mab 5C3. Monoclonal antibody  
10 MC192 against p75 receptor has also been demonstrated to have neurotrophic effects. Therefore, these antibodies and their functionally equivalent fragments can also serve as the binding agent **B** of the compound according to the present invention to deliver the conjugated therapeutic agent **TM** into the nerve cells.

15 Alternatively, peptidomimetics that are synthesized by incorporating unnatural amino acids or other organic molecules may serve as the binding agent **B** of the compound according to the present invention to deliver the conjugated therapeutic agent **TM** into the nerve cells. These synthetic peptide mimics are capable of binding to the nerve cell surface receptor  
20 and being internalized into the cell.

It is noted that the identification and selection of moieties which can serve as binding agents in the present invention can be readily performed by attaching an imaging moiety **IM** to the potential binding agent in order to detect whether the potential binding agent is internalized by the nerve  
25 cells. In this regard, combinatorial and mutagenesis approaches may be used to identify analogs, derivatives and fragments of known binding moieties which may also be used as binding moieties according to the present invention.

## 2. Therapeutic Moiety (TM)

An aspect of the present invention relates to the delivery of compounds into nerve cells which are non-cytotoxic to the nerve cells and perform a therapeutic function. Examples of therapeutic functions include, but are not limited to, treatment of neurological disorders, gene therapy, intracellular target imaging, cell sorting, or separation schemes. Examples of classes of therapeutic moieties include, but are not limited to adrenergic agents such as epinephrine, norepinephrine, dopamine, etenolol; analgesics such as opioids, codeine, oxycodone; anti-trauma agents; anti-viral agents such as acyclovir, gancyclovir, AZT, ddl, ddC; gene therapy agents such as; steroids such as cortisone, progesterone, estrogen; and hormones such as growth factors and interferons. Such compounds may optionally also include an imaging moiety, such as fluorescent moieties, for imaging intracellular components of the nerve cells.

A further aspect of the present invention relates to compositions and methods for improving the delivery of a therapeutic agent having a therapeutic activity intracellularly. This is accomplished by using therapeutic moieties which are charged. Cells have difficulty transporting charged molecules across cell membranes. According to this embodiment, the binding agent **B** serves to facilitate transport of a charged therapeutic moiety **TM** into a cell. Within the cell, the compound (i.e. the conjugate formed between **B** and **TM**) is metabolized to form a metabolite product that comprises the charged therapeutic moiety **TM**. The metabolite product is less prone to being transported across the cell membrane out of the cell relative to the conjugate because of the metabolism of the conjugate resulting in the separation of the therapeutic moiety **TM** from the binding agent **B**. The metabolite product is also less prone to being transported across the cell membrane out of the cell relative to a non-charged version of the therapeutic moiety due to the charge which the therapeutic moiety carries.

According to this embodiment, compounds are provided which comprise a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell, the cell metabolizing at least a portion of the compound to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the compound and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.

In one particular embodiment, the charged therapeutic moiety **TM** is a quaternary alkyl amine derivative of a therapeutic moiety. A particular example of a quaternary alkyl amine derivative of a therapeutic moiety **TM** is a quaternary alkyl amine of propoxycaine, shown in Table 3.

Also according to this embodiment, methods are provided which comprise administering a therapeutic agent to a patient in a form where the therapeutic agent comprises a charge and is conjugated to a protein having the biological activity of being transported across a cell membrane into a cell. Once within the cell, the cell metabolizes at least a portion of the compound to form a metabolite product that possesses the therapeutic activity of the therapeutic agent. The metabolite product is less prone to being transported across the cell membrane out of the cell relative to the compound because of the metabolism of the compound resulting separation of the therapeutic moiety from the protein, and is less prone to being transported across the cell membrane out of the cell relative to an uncharged version of the therapeutic agent.




This method may be used in conjunction with the conjugates of the present invention for selectively delivering a moiety to nerve cells. However, it is noted that charged therapeutic moieties can be used with binding agents that target cells other than nerve cells.

### 3. Linker (L)

According to the present invention, a binding agent **B** is linked to a therapeutic moiety **TM** by a linker **L**. In general, any method of linking a binding agent to a therapeutic moiety may be used and is intended to fall within the scope of the present invention.

Many different types of linkers have been developed for cross linking proteins and conjugating proteins or peptides with other agents. These linkers include zero-length cross linkers, homobifunctional cross-linkers, heterobifunctional cross-linkers and trifunctional cross-linkers. These linkers may have different susceptibility to cleavage under certain conditions. Depending on a particular application according to the present invention, an appropriate linker may be chosen. When an intracellular release of the agent from its conjugate is desired, a cleavable linker is chosen which is susceptible to cleavage by external stimuli such as light and heat, by intracellular enzymes, or by a particular microenvironment inside the cell.

In one embodiment, the linker **L** has one of the following general structures:



Wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ , and  $R_6$  are independently selected from the group consisting of alkyls, aryls, heteroaryls, cycloalkyls, cycloalkenes and heterocycloalkenes.

#### 4. Cleavable Linkers

One particular embodiment of the present invention relates to compounds which include a cleavable linker L. In some instances, the therapeutic moiety **TM** is more efficacious or potent when free from a carrier molecule such as a binding agent. In such instances, it is desirable to utilize a cleavable linker which allows the therapeutic moiety **TM** to be released from the compound once inside the cell.

Many cleavable linker groups have been developed which are susceptible to cleavage and by a wide variety of mechanisms. For example, linkers have been developed which may be cleaved by reduction of a disulfide bond, by irradiation of a photolabile bond, by hydrolysis of derivatized amino acid side chain, by serum complement-mediated hydrolysis, and by acid-catalyzed hydrolysis.

Examples of photolabile linkers that may be used include those linkers described in U.S. Patent Nos. 5,767,288 and No. 4,469,774.

Acid-labile linkers are preferred in the practice of the present invention by taking advantage of a cell's receptor-mediated endocytosis pathways. Receptors that are internalized by receptor-mediated endocytosis pass through acidified compartments known as endosomes or receptosomes. Since the interior of the endosomal compartment is kept acidic (pH~6.0) by ATP-driven H<sup>+</sup> pumps in the endosomal membrane that pump H<sup>+</sup> into the lumen from the cytosol, a change in pH within the nerve cell can be used to cause the acid-labile linker to be cleaved and release the therapeutic moiety. Examples of acid labile linkers which may be used include the cis-aconitic acid, cis-carboxylic alkatriene, polymaleic anhydride, and other acid labile linkers described in US Patent Nos. 5,563,250 and 5,505, 931.


#### 5. Examples Of Compounds According To The Present Invention

Table 2 provides several compounds according to the present invention. It is noted that in each instance, the particular therapeutic



moieties, binding moieties, and linkers shown may be interchanged with other suitable therapeutic moieties, binding moieties, and linkers. In this regard, the compounds shown in the table are intended to illustrate the diversity of compounds provided according to the present invention.


**TABLE 2**



**Acyclovir**

wherein


15 **B** is selected from the group consisting of nerve growth factors NGF, BDNF, NT-3, NT-4, NT-6, anti-neurotrophin receptor antibodies Mab 5C3 and Mab MC192.



**Acyclovir**

wherein

**B** is selected from the group consisting of nerve growth factors NGF, BDNF, NT-3, NT-4, NT-6, anti-neurotrophin receptor antibodies Mab 5C3 and Mab MC192.




wherein

**B** is selected from the group consisting of nerve growth factors NGF, BDNF, NT-3, NT-4, NT-6, anti-neurotrophin receptor antibodies MAb 5C3 and Mab MC192.

5

**TABLE 2-continued**

10




15

wherein

**B** is selected from the group consisting of nerve growth factors NGF, BDNF, NT-3, NT-4, NT-6, anti-neurotrophin receptor antibodies MAb 5C3 and Mab MC192.

20

25



wherein

**B** is selected from the group consisting of nerve growth factors NGF, BDNF, NT-3, NT-4, NT-6, anti-neurotrophin receptor antibodies MAb 5C3 and Mab MC192.

30

## 6. Examples Of Compounds For Treating Pain





Table 3 provides several therapeutic moieties which may be used in the compounds and methods of the present invention for treating pain. It is noted that any of the various binding moieties and linkers described herein may be employed with these therapeutic agents. Indicated in the table below as \* are preferred moieties for attaching linkers to the therapeutic moieties.

## 7. Examples Of Linkers

Table 4 provides a series of linkers for linking different therapeutic moieties and binding moieties together. As illustrated, linkers are provided for attaching moieties which have thiol (-SH), hydroxyl (-OH), and amino (-NH<sub>2</sub>) groups to the linkers. In these examples, neurotrohin is shown as the binding agent. However, it is noted that neurotrohin and these examples are intended to be exemplary only. Other linkers may also be used and are intended as part of the present invention.


TABLE 3

Pain - Steroidal anti-inflammatory agents



5



Pain - Non-steroidal anti-inflammatory agent



10



TABLE 3 (cont.)

Pain - Local anesthetic agents





5

Pain - Narcotic Agonists




Pain - Channel blockers



**TABLE 3 (cont.)**  
**Anti-neurodegenerative**

Tacrine HCl




$C_{13}H_{14}N_2 \cdot HCl$

Mol. Wt.: 234.73

**Antiviral**

Cidofovir




$C_8H_{14}N_4O_6P \cdot 2H_2O$

Mol. Wt.: 315.22

Table 4

Hydroxyl group conjugations




e.g., Steroids, Piroxicam, Acyclovir, Etorphine



5


Amino group conjugations

e.g., Propoxycaines, Gabapentin, Carbamazepine, Tacrine



10

Table 4 (cont.)  
Phosphate group conjugations




5




## 8. Synthetic Sequence For Attaching Acyclovir To NGF Via PMPI

Illustrated below is a synthetic sequence for the attachment of acyclovir to NGF via the linker PMPI.



Illustrated below is a synthetic sequence for the attachment of  
5 acyclovir to NGF via an imidazole linker.



linker (L) which in turn is conjugated with the therapeutic moiety (TM) are highlighted and underlined in Table 5.

**Table 5. Sequences of Examples of Human Neurotrophins**

5	NERVE GROWTH FACTOR (NGF) [SEQ ID NO: 1]:
1	SER SER SER HIS PRO ILE PHE HIS ARG GLY GLU PHE SER
	VAL CYS ASP SER VAL SER VAL TRP VAL GLY ASP <u>LYS</u> THR
10	THR ALA THR ASP ILE <u>LYS</u> GLY <u>LYS</u> GLU VAL MET VAL LEU
	GLY GLU VAL ASN ILE ASN ASN SER VAL PHE <u>LYS</u> GLN TYR
	PHE PHE GLU THR <u>LYS</u> CYS ARG ASP PRO ASN PRO VAL ASP
	SER GLY CYS ARG GLY ILE ASP SER <u>LYS</u> HIS TRP ASN SER
	TYR CYS THR THR THR HIS THR PHE VAL <u>LYS</u> ALA LEU THR
15	MET ASP GLY <u>LYS</u> GLN ALA ALA TRP ARG PHE ILE ARG ILE
	ASP THR ALA CYS VAL CYS VAL LEU SER ARG <u>LYS</u> ALA VAL
120	ARG ARG ALA
	BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) [SEQ ID NO: 2]:
1	HIS SER ASP PRO ALA ARG ARG GLY GLU LEU SER VAL CYS
20	ASP SER ILE SER GLU TRP VAL THR ALA ALA ASP <u>LYS</u> <u>LYS</u>
	THR ALA VAL ASP MET SER GLY GLY THR VAL THR VAL LEU
	GLU <u>LYS</u> VAL PRO VAL SER <u>LYS</u> GLY GLN LEU <u>LYS</u> GLN TYR
	PHE TYR GLU THR <u>LYS</u> CYS ASN PRO MET GLY TYR THR <u>LYS</u>
	GLU GLY CYS ARG GLY ILE ASP <u>LYS</u> ARG HIS TRP ASN SER
25	GLN CYS ARG THR THR GLN SER TYR VAL ARG ALA LEU THR
	MET ASP SER <u>LYS</u> <u>LYS</u> ARG ILE GLY TRP ARG PHE ILE ARG
	ILE ASP THR SER CYS VAL CYS THR LEU THR ILE <u>LYS</u> ARG
119	GLY ARG
30	NEUROTROPHIN-3 (NT-3) [SEQ ID NO: 3]:
1	TYR ALA GLU HIS <u>LYS</u> SER HIS ARG GLY GLU TYR SER VAL
	CYS ASP SER GLU SER LEU TRP VAL THR ASP <u>LYS</u> SER SER
	ALA ILE ASP ILE ARG GLY HIS GLN VAL THR VAL LEU GLY
	GLU ILE <u>LYS</u> THR GLY ASN SER PRO VAL <u>LYS</u> GLN TYR PHE
35	TYR GLU THR ARG CYS <u>LYS</u> GLU ALA ARG PRO VAL <u>LYS</u> ASN
	GLY CYS ARG GLY ILE ASP ASP <u>LYS</u> HIS TRP ASN SER GLN
	CYS <u>LYS</u> THR SER GLN THR TYR VAL ARG ALA LEU THR SER
	GLU ASN ASN <u>LYS</u> LEU VAL GLY TRP ARG TRP ILE ARG ILE
	ASP THR SER CYS VAL CYS ALA LEU SER ARG <u>LYS</u> ILE GLY
40	119 ARG THR
	NEUROTROPHIN-4 (NT-4) [SEQ ID NO: 4]:
1	GLY VAL SER GLU THR ALA PRO ALA SER ARG ARG GLY GLU
	LEU ALA VAL CYS ASP ALA VAL SER GLY TRP VAL THR ASP
45	ARG ARG THR ALA VAL ASP LEU ARG GLY ARG GLU VAL GLU
	VAL LEU GLY GLU VAL PRO ALA ALA GLY GLY SER PRO LEU
	ARG GLN TYR PHE PHE GLU THR ARG CYS <u>LYS</u> ALA ASP ASN
	ALA GLU GLU GLY GLY PRO GLY ALA GLY GLY GLY CYS
	ARG GLY VAL ASP ARG ARG HIS TRP VAL SER GLU CYS <u>LYS</u>
50	ALA <u>LYS</u> GLN SER TYR VAL ARG ALA LEU THR ALA ASP ALA
	GLN GLY ARG VAL GLY TRP ARG TRP ILE ARG ILE ASP THR
130	ALA CYS VAL CYS THR LEU LEU SER ARG THR GLY ARG ALA

## 11. **Methods For Using Compounds Of The Present Invention**

Described below are several methods for formulating and administering the compounds of the present invention. The compounds of the present invention may be employed in these and other applications.

5

### a. **Pharmaceutical Formulations Utilizing Compositions Of The Present Invention**

The compounds of the present invention may be incorporated into a variety of pharmaceutical compositions including, but not limited to: a sterile injectable solution or suspension; hard or soft gelatin capsules; tablets; emulsions; aqueous suspensions, dispersions, and solutions; suppositories. Other pharmaceutically suitable formulations for delivering the compounds of the present invention to nerve cells may also be used and are intended to fall within the scope of the present invention.

15

### b. **Routes of Administration**

The compounds according to the present invention can be administered orally, by subcutaneous or other injection, intravenously, intracerebrally, intramuscularly, parenterally, transdermally, nasally or rectally. The form in which the compound is administered depends at least in part on the route by which the compound is administered.

20

While the present invention is disclosed with reference to preferred embodiments and examples detailed above, it is to be understood that these examples are intended in an illustrative rather than limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, which modifications will be within the spirit of the invention and the scope of the appended claims. The patents, papers, and books cited in this application are to be incorporated herein in their entirety.

30

## CLAIMS

What is claimed is:

1. A method for improving intracellular administration of a therapeutic agent comprising:

contacting cells with a compound comprising a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell; and

having the cell transport the compound into the cell where the cell metabolizes at least a portion of the compound to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the compound and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.

2. A method according to claim 1 wherein the charged derivative of the therapeutic agent is a quarternary alkyl amine.

3. A method according to claim 1 wherein the therapeutic agent is propoxycaïne and the charged derivative of the therapeutic agent is a quarternary alkyl amine of propoxycaïne.

4. A method according to claim 1 wherein the therapeutic agent is propoxycaïne and the charged derivative of the therapeutic agent is a quarternary alkyl amine of etorphine.

5. A method according to claim 1 wherein the protein is selected from the group consisting of a nucleic acid sequence, a peptide, a peptidomimetic, an antibody and an antibody fragment.
6. A method according to claim 1 wherein protein is selected from the group consisting of nerve growth factors and analogs, derivatives and fragments of nerve growth factors.
7. A method according to claim 1 wherein the protein is selected from the group consisting of antibodies and antibody fragments that selectively bind to nerve cell surface receptors.
8. A method according to claim 1 wherein the protein is a DNA or RNA ligand that functions as an antagonist of nerve growth factors or inhibits binding of other growth factors to nerve cell surface receptors.
9. A method according to claim 1 wherein the protein is a synthetic peptide that binds to nerve cell surface receptors and has agonist or antagonist activity of nerve growth factors.
10. A method according to claim 1 wherein the protein is selected from the group consisting of anti-human trkA monoclonal antibody 5C3 and anti-human p75 monoclonal antibody MC192.
11. A method according to claim 1 wherein the protein is selected from the group consisting of NGF, BDNF, NT-3, NT-4, and NT-6.
12. A method according to claim 1 wherein the protein is selected from the group consisting of NGF, a fragment or derivative of NGF, a protein capable of competing with NGF for binding to a NGF receptor, BDNF, a fragment or derivative of BDNF, and a protein capable of competing with BDNF for binding to a BDNF receptor.

13. A compound comprising:  
a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell, the cell metabolizing at least a portion of the compound to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the compound and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.
14. A compound according to claim 13 wherein the charged derivative of the therapeutic agent is a quaternary alkyl amine.
15. A compound according to claim 13 wherein the therapeutic agent is propoxycaine and the charged derivative of the therapeutic agent is a quaternary alkyl amine of propoxycaine.
16. A compound according to claim 13 wherein the therapeutic agent is propoxycaine and the charged derivative of the therapeutic agent is a quaternary alkyl amine of etorphine.
17. A compound according to claim 13 wherein the protein is selected from the group consisting of a nucleic acid sequence, a peptide, a peptidomimetic, an antibody and an antibody fragment.
18. A compound according to claim 13 wherein protein is selected from the group consisting of nerve growth factors and analogs, derivatives and fragments of nerve growth factors.

19. A compound according to claim 13 wherein the protein is selected from the group consisting of antibodies and antibody fragments that selectively bind to nerve cell surface receptors.

20. A compound according to claim 13 wherein the protein is a DNA or RNA ligand that functions as an antagonist of nerve growth factors or inhibits binding of other growth factors to nerve cell surface receptors.

21. A compound according to claim 13 wherein the protein is a synthetic peptide that binds to nerve cell surface receptors and has agonist or antagonist activity of nerve growth factors.

22. A compound according to claim 13 wherein the protein is selected from the group consisting of anti-human trkA monoclonal antibody 5C3 and anti-human p75 monoclonal antibody MC192.

23. A compound according to claim 13 wherein the protein is selected from the group consisting of NGF, BDNF, NT-3, NT-4, and NT-6.

24. A compound according to claim 13 wherein the protein is selected from the group consisting of NGF, a fragment or derivative of NGF, a protein capable of competing with NGF for binding to a NGF receptor, BDNF, a fragment or derivative of BDNF, and a protein capable of competing with BDNF for binding to a BDNF receptor.



**Compounds For Intracellular Delivery  
Of Therapeutic Moieties To Nerve Cells**

Inventors: Craig Hill, Steve Kahl,  
Robert R. Webb, and Constance A. McKee

**ABSTRACT**

A method for improving intracellular administration of a therapeutic agent is provided comprising: contacting cells with a compound comprising  
5 a charged derivative of a therapeutic agent having a therapeutic activity,  
the charged derivative being conjugated to a protein having a biological  
activity of being transported across a cell membrane into a cell; and having  
the cell transport the compound into the cell where the cell metabolizes at  
least a portion of the compound to form a charged metabolite product that  
10 possesses the therapeutic activity of the therapeutic agent, the charged  
metabolite product being less prone to being transported across the cell  
membrane out of the cell relative to the compound and less prone to being  
transported across the cell membrane out of the cell relative to the  
therapeutic agent.

15

# SEQUENCE LISTING

<110> Hill, Craig  
Kahl, Steve  
Webb, Robert R.  
McKee, Constance A.

<120> COMPOUNDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC  
MOIETIES TO NERVE CELLS

<130> Seq Listing 16778-704

<140>

<141>

<150> 09/217,037

<151> 1998-12-21

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 120

<212> PRT

<213> Homo sapiens

<400> 1

Ser	Ser	Ser	His	Pro	Ile	Phe	His	Arg	Gly	Glu	Phe	Ser	Val	Cys	Asp
1				5					10					15	

Ser	Val	Ser	Val	Trp	Val	Gly	Asp	Lys	Thr	Thr	Ala	Thr	Asp	Ile	Lys
			20					25						30	

Gly	Lys	Glu	Val	Met	Val	Leu	Gly	Glu	Val	Asn	Ile	Asn	Asn	Ser	Val
		35					40							45	

Phe	Lys	Gln	Tyr	Phe	Phe	Glu	Thr	Lys	Cys	Arg	Asp	Pro	Asn	Pro	Val
		50				55						60			

Asp	Ser	Gly	Cys	Arg	Gly	Ile	Asp	Ser	Lys	His	Trp	Asn	Ser	Tyr	Cys
65					70					75				80	

Thr	Thr	Thr	His	Thr	Phe	Val	Lys	Ala	Leu	Thr	Met	Asp	Gly	Lys	Gln
				85					90					95	

Ala	Ala	Trp	Arg	Phe	Ile	Arg	Ile	Asp	Thr	Ala	Cys	Val	Cys	Val	Leu
		100					105						110		

Ser Arg Lys Ala Val Arg Arg Ala  
 115 120

<210> 2  
 <211> 119  
 <212> PRT  
 <213> Homo sapiens

<400> 2  
 His Ser Asp Pro Ala Arg Arg Gly Glu Leu Ser Val Cys Asp Ser Ile  
 1 5 10 15

Ser Glu Trp Val Thr Ala Ala Asp Lys Lys Thr Ala Val Asp Met Ser  
 20 25 30

Gly Gly Thr Val Thr Val Leu Glu Lys Val Pro Val Ser Lys Gly Gln  
 35 40 45

Leu Lys Gln Tyr Phe Tyr Glu Thr Lys Cys Asn Pro Met Gly Tyr Thr  
 50 55 60

Lys Glu Gly Cys Arg Gly Ile Asp Lys Arg His Trp Asn Ser Gln Cys  
 65 70 75 80

Arg Thr Thr Gln Ser Tyr Val Arg Ala Leu Thr Met Asp Ser Lys Lys  
 85 90 95

Arg Ile Gly Trp Arg Phe Ile Arg Ile Asp Thr Ser Cys Val Cys Thr  
 100 105 110

Leu Thr Ile Lys Arg Gly Arg  
 115

<210> 3  
 <211> 119  
 <212> PRT  
 <213> Homo sapiens

<400> 3  
 Tyr Ala Glu His Lys Ser His Arg Gly Glu Tyr Ser Val Cys Asp Ser  
 1 5 10 15

Glu Ser Leu Trp Val Thr Asp Lys Ser Ser Ala Ile Asp Ile Arg Gly  
 20 25 30

His Gln Val Thr Val Leu Gly Glu Ile Lys Thr Gly Asn Ser Pro Val  
35 40 45

Lys Gln Tyr Phe Tyr Glu Thr Arg Cys Lys Glu Ala Arg Pro Val Lys  
50 55 60

Asn Gly Cys Arg Gly Ile Asp Asp Lys His Trp Asn Ser Gln Cys Lys  
65 70 75 80

Thr Ser Gln Thr Tyr Val Arg Ala Leu Thr Ser Glu Asn Asn Lys Leu  
85 90 95

Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ser Cys Val Cys Ala Leu  
100 105 110

Ser Arg Lys Ile Gly Arg Thr  
115

<210> 4

<211> 130

<212> PRT

<213> Homo sapiens

<400> 4

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala Val  
1 5 10 15

Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala Val Asp  
20 25 30

Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro Ala Ala Gly  
35 40 45

Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg Cys Lys Ala Asp  
50 55 60

Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly Gly Cys Arg Gly  
65 70 75 80

Val Asp Arg Arg His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr  
85 90 95

Val Arg Ala Leu Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg Trp  
100 105 110

Ile Arg Ile Asp Thr Ala Cys Val Cys Thr Leu Leu Ser Arg Thr Gly  
115 120 125

Arg Ala  
130

Case	Age	Sex	Duration of illness (yr)	Initial symptoms	Course	Outcome
1	45	M	10	Headache, vomiting, weight loss	Progressive	Death
2	55	F	5	Headache, vomiting, weight loss	Progressive	Death
3	65	M	15	Headache, vomiting, weight loss	Progressive	Death
4	75	F	20	Headache, vomiting, weight loss	Progressive	Death
5	85	M	25	Headache, vomiting, weight loss	Progressive	Death
6	95	F	30	Headache, vomiting, weight loss	Progressive	Death
7	105	M	35	Headache, vomiting, weight loss	Progressive	Death
8	115	F	40	Headache, vomiting, weight loss	Progressive	Death
9	125	M	45	Headache, vomiting, weight loss	Progressive	Death
10	135	F	50	Headache, vomiting, weight loss	Progressive	Death
11	145	M	55	Headache, vomiting, weight loss	Progressive	Death
12	155	F	60	Headache, vomiting, weight loss	Progressive	Death
13	165	M	65	Headache, vomiting, weight loss	Progressive	Death
14	175	F	70	Headache, vomiting, weight loss	Progressive	Death
15	185	M	75	Headache, vomiting, weight loss	Progressive	Death
16	195	F	80	Headache, vomiting, weight loss	Progressive	Death
17	205	M	85	Headache, vomiting, weight loss	Progressive	Death
18	215	F	90	Headache, vomiting, weight loss	Progressive	Death
19	225	M	95	Headache, vomiting, weight loss	Progressive	Death
20	235	F	100	Headache, vomiting, weight loss	Progressive	Death